{"id":5603,"date":"2016-05-04T14:54:02","date_gmt":"2016-05-04T14:54:02","guid":{"rendered":"https:\/\/p-bio.org\/documents-and-strategies\/"},"modified":"2023-03-06T10:51:01","modified_gmt":"2023-03-06T10:51:01","slug":"documents-and-strategies","status":"publish","type":"page","link":"https:\/\/p-bio.org\/en\/documents-and-strategies\/","title":{"rendered":"Documents and Strategies"},"content":{"rendered":"\n<p>\n          <strong>\n            <u>&#8211; Portugal Biotech Study<\/u>\n          <\/strong>\n        <\/p>\n\n<figure class=\"wp-block-image size-large is-resized\"><img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/p-bio.org\/wp-content\/uploads\/2022\/03\/Imagem4.png\" alt=\"\" class=\"wp-image-3001\" width=\"227\" height=\"326\" srcset=\"https:\/\/p-bio.org\/wp-content\/uploads\/2022\/03\/Imagem4.png 377w, https:\/\/p-bio.org\/wp-content\/uploads\/2022\/03\/Imagem4-209x300.png 209w\" sizes=\"(max-width: 227px) 100vw, 227px\" \/><\/figure>\n<p style=\"text-align: left;\">O  <a href=\"https:\/\/p-bio.org\/pt\/estudo-portugal-biotech\/\">Study &#8220;Portugal Biotech:<\/a>  trends, opportunities and challenges in the Biotechnology sector in Portugal&#8221; launched in late 2021, was developed under BioData.pt (Portuguese biological data infrastructure) resulting from a broader and more complete analysis of an initial study on the Portuguese Biotechnology Industry, launched by P-BIO in 2016. Analysis.<\/p>\n<p>Analysis <strong><br \/>\n  <u>SWOT ANALYSIS<\/u><br \/>\n<\/strong> of the biotechnology sector in Portugal:<\/p>\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/p-bio.org\/wp-content\/uploads\/2022\/03\/image-1.png\" alt=\"\" class=\"wp-image-3004\" width=\"653\" height=\"249\" srcset=\"https:\/\/p-bio.org\/wp-content\/uploads\/2022\/03\/image-1.png 923w, https:\/\/p-bio.org\/wp-content\/uploads\/2022\/03\/image-1-300x115.png 300w, https:\/\/p-bio.org\/wp-content\/uploads\/2022\/03\/image-1-768x294.png 768w\" sizes=\"(max-width: 653px) 100vw, 653px\" \/><\/figure>\n\n<hr class=\"wp-block-separator\"\/>\n\n<p>&#8211; <strong>\n  <u>BioHealth Strategy 2030<\/u>\n<\/strong><\/p>\n\n<p>What should be the strategic objectives of this bet? Where do we want to be in 5 or 10 years? We want Portugal to become an international Hub for Health R&amp;DT and to position itself as the European factory for products for the Health vertical and products with high added value such as drugs, new molecules and medical devices, following a challenge from Commissioner Stella Kyriakides before the PE12. Following a methodology already used by Porto Business School in a 2014 proposal13, the goal for 2030 should be to significantly increase the weight of this sector in GDP and have concrete and measurable targets:<\/p>\n\n<ul class=\"wp-block-list\" type=\"1\"><li>Balance the trade balance in the drug and medical device sector by increasing exports;<\/li><li>Have 10 innovative medicines (of all classes, including advanced therapies) in Portugal or based on Portuguese science;<\/li><li>Have 10 innovative medical devices developed in Portugal or based on Portuguese Science;<\/li><li>Attract clinical development of drugs and medical devices, making Portugal a Hub for this purpose (having as a metric to match Belgium in clinical trials);<\/li><li>Tripling the number of patent applications;<\/li><li>Triple investment in business R&amp;DT;<\/li><li>Tripling the % of PhDs in companies.<\/li><\/ul>\n\n<p>The creation of a Thematic Operational Program Bio-Health 2030 (immediately with the reprogramming of PT2020), should contemplate 2 major axes within the cluster: Portugal an R&amp;DT Hub and Portugal the factory of Europe:<\/p>\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"820\" height=\"561\" src=\"https:\/\/p-bio.org\/wp-content\/uploads\/2022\/03\/image-2.png\" alt=\"\" class=\"wp-image-3008\" srcset=\"https:\/\/p-bio.org\/wp-content\/uploads\/2022\/03\/image-2.png 820w, https:\/\/p-bio.org\/wp-content\/uploads\/2022\/03\/image-2-300x205.png 300w, https:\/\/p-bio.org\/wp-content\/uploads\/2022\/03\/image-2-768x525.png 768w\" sizes=\"(max-width: 820px) 100vw, 820px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; Portugal Biotech Study O Study &#8220;Portugal Biotech: trends, opportunities and challenges in the Biotechnology sector in Portugal&#8221; launched in late 2021, was developed under BioData.pt (Portuguese biological data infrastructure) [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4733,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"class_list":["post-5603","page","type-page","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/pages\/5603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/comments?post=5603"}],"version-history":[{"count":2,"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/pages\/5603\/revisions"}],"predecessor-version":[{"id":5605,"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/pages\/5603\/revisions\/5605"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/media\/4733"}],"wp:attachment":[{"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/media?parent=5603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}